Ligand ID: LVY


Drugbank ID:
DB00480
(Lenalidomide)


Indication:
Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Get human targets for LVY in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'LVY' AND SARS-RELATED PROTEINS ONLY

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V30_B_LVYB151_1
(CEREBLON ISOFORM 4)		1x7q HLA, A-11
NUCLEOCAPSID PEPTIDE
(Homo
sapiens)		4 / 8
ASN A  66
PRO C   4
PHE C   3
TYR A 171
1.66A19.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V30_A_LVYA151_1
(CEREBLON ISOFORM 4)		1x7q HLA, A-11
NUCLEOCAPSID PEPTIDE
(Homo
sapiens)		4 / 7
ASN A  66
PRO C   4
PHE C   3
TYR A 171
1.72A19.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V30_A_LVYA151_1
(CEREBLON ISOFORM 4)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		4 / 7
ASN S 473
PRO S 462
PHE S 460
TYR A 442
1.66A19.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V30_B_LVYB151_1
(CEREBLON ISOFORM 4)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		4 / 8
ASN S 473
PRO S 462
PHE S 460
TYR A 442
1.69A19.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5FQD_E_LVYE1438_1
(PROTEIN CEREBLON
CASEIN KINASE I
ISOFORM ALPHA)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
HIS A 401
GLU A 375
SER A 409
ILE A 379
GLY A 377
1.75A21.04
20.30
None
ZN  A 901 (-3.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V30_B_LVYB151_1
(CEREBLON ISOFORM 4)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 8
MET A1032
PHE A 870
TRP A 868
TYR C1029
1.48A8.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V30_B_LVYB151_1
(CEREBLON ISOFORM 4)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASN B1090
PRO B1051
TRP A 868
TYR A 886
1.75A8.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V30_A_LVYA151_1
(CEREBLON ISOFORM 4)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ASN B1090
PRO B1051
TRP A 868
TYR A 886
1.67A8.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5FQD_B_LVYB1438_1
(PROTEIN CEREBLON
CASEIN KINASE I
ISOFORM ALPHA)		6m1d ACE2
(Homo
sapiens)		5 / 11
HIS B 401
GLU B 375
HIS B 374
PHE B 314
GLY B 377
1.55A19.72
17.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5FQD_E_LVYE1438_1
(PROTEIN CEREBLON
CASEIN KINASE I
ISOFORM ALPHA)		6m1d ACE2
(Homo
sapiens)		5 / 12
HIS B 401
GLU B 375
HIS B 374
PHE B 314
GLY B 377
1.54A19.72
17.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5FQD_E_LVYE1438_1
(PROTEIN CEREBLON
CASEIN KINASE I
ISOFORM ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
PRO C 593
SER C 118
PHE C 283
ILE C 492
GLY C 490
1.68A19.82
19.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V30_B_LVYB151_1
(CEREBLON ISOFORM 4)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
MET A1032
PHE A 870
TRP A 868
TYR B1029
1.33A7.20
None